Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
Advances in Therapy · 2026-04 · 43 (4) · 1601-1621
DOI: 10.1007/s12325-025-03465-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Advances in Therapy, online erschienen am 13.02.2026. Verfasst von Nicolas Girard und 16 weiteren Autor:innen. Beteiligte Einrichtung: Curie-Montsouris Thorax Institute, Institut Curie, Paris, France. nicolas.girard2@curie.fr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Acrylamides, Aniline Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo Europe, Université de Versailles Saint-Quentin-en-Yvelines.
Abstract (Originalsprache)
INTRODUCTION: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is a standard first-line (1L) treatment for advanced/metastatic EGFR non-small cell lung cancer (NSCLC). Despite improved overall survival (OS) and progression-free survival (PFS) compared to earlier generation TKIs, resistance and disease progression are common. No standardized second-line (2L) treatment exists for patients who progress after 1L osimertinib. This study assessed real-world (rw) treatment patterns and clinical outcomes in French patients with advanced/metastatic NSCLC who received 2L therapy post-osimertinib progression. METHODS: This retrospective, observational study used the Epidemio-Strategy and Medical Economics (ESME) LC database (NCT03848052) (January 1, 2015-2023; data extraction September 2023). Patients ≥ 18 years with confirmed advanced/metastatic NSCLC, treated with 1L osimertinib, and documented 2L therapy were included. The study assessed patient characteristics, rw treatment patterns, rwOS, and rwPFS. RESULTS: Among 284 patients (71.1% female, median age 67), 67% initiated 2L treatment in 2021 or later. The median number of metastases at 2L initiation was three, with bone (65.1%) and brain (56.6%) as the most common sites; 34% of brain metastases were symptomatic. The 2L treatments included platinum-based chemotherapy (50%), EGFR TKI-based therapy (29.9%), immunotherapy (9.9%), and other regimens (10.2%). Median rwOS from 2L initiation was 10.1 (95% CI 9.2-12.1) months, and median rwPFS was 4.1 (95% CI 3.3-4.8) months. Among patients with brain metastases, median rwOS was 8.7 (95% CI 7.1-11.9) months for asymptomatic and 10.7 (95% CI 9.4-12.9) months for symptomatic patients vs 11.8 (95% CI 9.1-17.4) months in patients without brain metastases. Patients with liver metastases had a median rwOS of 8.2 (95% CI 6.4-9.6) months vs 12.3 (95% CI 10.2-14.3) months in those without. CONCLUSIONS: Clinical outcomes for patients receiving 2L therapy post-osimertinib progression remain poor, highlighting an unmet need, particularly for those with brain and liver metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Curie-Montsouris Thorax Institute, Institut Curie, Paris, France. nicolas.girard2@curie.fr.
- Health Data and Partnership Depatment, Unicancer, Paris Cedex, France.
- Global Oncology Value Access and Pricing, Daiichi Sankyo Europe GmbH, Munich, Germany.
- Data Intelligence, Center of Excellence, Daiichi Sankyo, Inc., Basking Ridge, USA.
- Global Oncology Value Access and Pricing, Daiichi Sankyo, Inc., Basking Ridge, USA.
- Global Oncology Medical Affairs, Daiichi Sankyo Europe GmbH, Munich, Germany.
Förderung
- Daiichi Sankyo Europe
- Université de Versailles Saint-Quentin-en-Yvelines
Zitieren
APA
Girard, N., Macouillard, P., Byng, D., Meng, J., Coerts, F., Hunter, S., Struebing, A., Xiong, Y., Park, S., Haq, M. I., Tymejczyk, O., Chouaid, C., Audigier-Valette, C., Debieuvre, D., Quantin, X., Bosquet, L., & Pérol, M. (2026). Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients. Advances in Therapy, 43(4), 1601-1621. https://doi.org/10.1007/s12325-025-03465-4
Vancouver
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, et al. Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients. Advances in Therapy. 2026;43(4):1601-1621. doi:10.1007/s12325-025-03465-4
BibTeX
@article{Girard2026,
author = {Girard, Nicolas and Macouillard, Pauline and Byng, Danalyn and Meng, Jie and Coerts, Friso and Hunter, Shannon and Struebing, Alessandria and Xiong, Yan and Park, Sarah and Haq, M Inaam and Tymejczyk, Olga and Chouaid, Christos and Audigier-Valette, Clarisse and Debieuvre, Didier and Quantin, Xavier and Bosquet, Lise and Pérol, Maurice},
title = {Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients},
journal = {Advances in Therapy},
year = {2026},
volume = {43},
number = {4},
pages = {1601--1621},
doi = {10.1007/s12325-025-03465-4}
}
EUVIMED